The c-Src/LIST positive feedback loop sustains tumor progression and chemoresistance
Chemotherapy resistance and treatment failure hinder clinical cancer treatment. Src, the first mammalian proto-oncogene to be discovered, is a valuable anti-cancer therapeutic target. Several c-Src inhibitors have reached the clinical stage, but drug resistance remains a challenge during treatment. Herein, we uncovered a positive feedback loop between a previously uncharacterized long non-coding RNA (lncRNA), which we renamed LncRNA Inducing c-Src Tumor-Promoting Function (LIST), and c-Src.